24/7 Market News Snapshot 12 February, 2025 – Xilio Therapeutics, Inc. Common Stock (NASDAQ:XLO)

February 12, 2025

DENVER, Colo., 12 February, 2025 (247marketnews.com) – (Nasdaq:XLO) are discussed in this article.
Xilio Therapeutics, Inc. (Nasdaq:XLO) is witnessing a remarkable surge in its market value, experiencing an extraordinary 142.47% increase in pre-market trading, where shares are now valued at $1.593, compared to the previous close of $0.657. This upswing is buoyed by a significant trading volume of 8.56 million shares, reflecting strong investor enthusiasm and optimism regarding the company’s trajectory in the competitive biotechnology landscape.

Amid this bullish market activity, Xilio has announced the launch of three transformative preclinical programs aimed at advancing tumor-activated immunotherapy treatments. Focused on enhancing patient outcomes while minimizing systemic side effects, these programs represent a bold step forward in the realm of cancer therapy. Central to this initiative is a collaboration with AbbVie, entailing an upfront payment of $52 million, which capitalizes on Xilio’s proprietary tumor activation technology to develop next-generation tumor-activated immunotherapies, including cutting-edge masked T cell engagers.

“Today marks a pivotal moment for Xilio,” stated René Russo, Pharm.D., president and CEO of Xilio. “Our unique masking technology allows for the selective activation of T cells within the tumor microenvironment, enhancing the efficacy and tolerability of our treatments.” The three tumor-associated antigens being targeted are prostate-specific membrane antigen (PSMA), claudin 18.2 (CLDN18.2), and six-transmembrane epithelial antigen of prostate 1 (STEAP1), each promising to revolutionize cancer immunotherapy by improving therapeutic outcomes while minimizing toxicity.

The collaboration with AbbVie also offers the potential for additional milestone payments exceeding $2.1 billion, highlighting the extensive growth prospects of Xilio’s innovative pipeline. As Xilio positions itself at the forefront of immuno-oncology, the company is poised for impactful advancements in cancer treatment as it prepares to discuss these developments further in an upcoming investor conference call.

Related news for (XLO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.